Together with arginine-glycine-aspartic acid (RGD) peptide, these modified EVs contributed to elevated numbers of CD8+ T cells and the ratio of M1/M2 macrophages, eventually resulting in anti-tumor effects and an increased survival rate in glioblastoma mouse models [148]. Here, CD8A is linked to neoplasm.